Clinical Trials
16 trialsNCT07172958 2026-05-22
SABRE
Children's National Research Institute
Phase 1 Recruiting
NCT04897321 2026-05-19
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT04901702 2026-05-19
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT07584499 2026-05-13
MRG003
Sun Yat-sen University
Phase 1 Recruiting
NCT05985161 2026-05-06
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04322318 2026-05-05
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Children's Oncology Group
Phase 2 Recruiting
NCT04851119 2026-05-05
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
Phase 1/2 Recruiting
NCT04968990 2026-04-23
Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT03810651 2026-04-15
Pencil Beam Scanning in Patients With Renal Tumors
Children's Hospital of Philadelphia
Phase EARLY_PHASE1 Recruiting
NCT04308330 2026-04-15
NYMC195
New York Medical College
Phase 1 Recruiting
NCT04715191 2026-04-06
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
Phase 1 Recruiting
NCT05384821 2026-03-18
MetroWilms
Centre Oscar Lambret
Phase 1/2 Recruiting
NCT07148050 2026-02-17
IMPACT
Seattle Children's Hospital
Phase 1 Recruiting
NCT06198296 2025-11-03
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Baylor College of Medicine
Phase 1 Recruiting
NCT05135975 2025-08-12
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Nationwide Children's Hospital
Phase 2 Recruiting
NCT05765084 2024-05-16
Immuno-MESODEC
University Hospital, Antwerp
Phase 1/2 Recruiting